Tozasertib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTozasertib
Drug Alias Name托泽色替tozasertibum托扎舍替陶扎色替VX-680 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsSerine/threonine-protein kinase Aurora-C inhibitors +[4] 
TargetsSerine/threonine-protein kinase Aurora-ATyrosine-protein kinase receptor FLT3Serine/threonine-protein kinase Aurora-C +[4] 
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG